Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.701 USD | -2.26% | -11.12% | -90.84% |
May. 21 | FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD | CI |
May. 08 | Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 4.56M |
---|---|---|---|---|---|
Net income 2024 * | -10M | Net income 2025 * | -13M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.34
x | P/E ratio 2025 * |
-0.3
x | Employees | 13 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.57% |
1 day | -2.26% | ||
1 week | -11.12% | ||
1 month | -32.60% | ||
3 months | -47.69% | ||
6 months | -88.55% | ||
Current year | -90.84% |
Managers | Title | Age | Since |
---|---|---|---|
Matthew Brams
FOU | Founder | 61 | 12-12-31 |
Raul Silva
FOU | Founder | 67 | 12-12-31 |
Shane Schaffer
CEO | Chief Executive Officer | 49 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Peter Werth
BRD | Director/Board Member | 85 | 18-05-31 |
Jeffrey Ervin
BRD | Director/Board Member | 46 | Feb. 12 |
Shane Schaffer
CEO | Chief Executive Officer | 49 | 12-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 0.701 | -2.26% | 62,576 |
24-05-30 | 0.7172 | +2.46% | 102,091 |
24-05-29 | 0.7 | -1.09% | 135,623 |
24-05-28 | 0.7077 | -10.27% | 339,816 |
24-05-24 | 0.7887 | -4.40% | 158,811 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-90.84% | 4.56M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- CING Stock